Simcere Entered into an Exclusive License Agreement with Idorsia for Daridorexant in China
Shots:
- Idorsia to receive $30M up front and will be eligible to receive an additional fees of $20M upon regulatory approval & commercial milestones along with royalties based on future sales
- Simcere to get an exclusive right to develop and commercialize daridorexant in the Greater China region (Mainland China, Hong Kong, and Macau) & will be responsible for funding and conducting a local development program with Chinese patients
- Daridorexant is a dual orexin receptor antagonist that blocks the binding of the wake-promoting neuropeptides orexins. Additionally, Sanbexin was available in the markets for acute ischemic stroke, and daridorexant will increase Simcere's pipeline of CNS products in China
Ref: PRNewswire | Image: Simcere
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
